Aegerion Settles Criminal and Civil Probe of Promotional Practices, REMS and HIPAA Compliance, and Patient Assistance Programs

by Skadden, Arps, Slate, Meagher & Flom LLP
Contact

Skadden, Arps, Slate, Meagher & Flom LLP

On September 22, 2017, Aegerion Pharmaceuticals resolved a wide-ranging probe by the Department of Justice (DOJ) regarding the company’s U.S. commercial activities relating to Juxtapid, a lipid-lowering agent for the treatment of homozygous familial hypercholesterolemia (HoFH).1 As detailed below, DOJ relied on a number of statutes and a complex web of agreements to address a wide array of alleged misconduct, including:

  • two misdemeanor violations of the federal Food, Drug and Cosmetic Act (FDCA), with $7.2 million in criminal fines and forfeiture, to resolve alleged misbranding in the form of off-label promotion and noncompliance with an FDA-mandated Risk Evaluation and Mitigation Strategy (REMS);
  • a deferred prosecution agreement (DPA) to resolve charges of conspiracy to violate the Health Insurance Portability and Accountability Act (HIPAA); and
  • a $28.8 million civil False Claims Act settlement (and related settlements with various states) to resolve allegations relating to Aegerion’s promotional and patient assistance program activities.

In addition, the company agreed to a series of forward-looking measures, including a corporate integrity agreement (CIA), an FDA consent decree of permanent injunction and extensive compliance obligations incorporated into the plea agreement and DPA.

Key Takeaways

  • Criminal FDCA charges and imposition of a consent decree demonstrate that the government will still pursue criminal liability for off-label promotional activities and has expanded its focus to REMS compliance.
  • The DPA for HIPAA violations highlights the risks for pharmaceutical companies that handle protected health information, while the DPA’s compliance provisions provide guidance for establishing privacy controls within drug and device companies.
  • The civil FCA resolution is the second one setting forth the government’s theory that donations to a copay charity may violate the Anti-Kickback Statute (AKS) where the charity lacks independence from the manufacturer.
  • The CIA represents the most recent government guidance regarding controls intended to ensure a manufacturer’s charitable donations do not run afoul of the AKS, and also continues the trend of imposing demanding oversight requirements in recent CIAs involving pharmaceutical companies.
  • Whistleblowers continue to be a primary catalyst for DOJ investigations, with the three relators in this case receiving a total of $4.7 million.2

FDCA Used to Impose Criminal Liability for Misbranding and REMS Noncompliance

Two components of the settlement — the criminal plea agreement and the FDA consent decree — resolve Aegerion’s FDCA liability. The factual basis for that liability is set forth in an Information that charges two separate misdemeanor FDCA violations.

Promotion of Juxtapid for Unapproved Uses. The Information charges that Aegerion misbranded Juxtapid by promoting it for uses for which the drug’s label lacked adequate directions for use, in violation of 21 U.S.C. § 352(f). The Information asserted that Aegerion:

  • sought and received Orphan approval for Juxtapid because it was intended to treat HoFH, a malady expected to occur in approximately one in 1 million patients;
  • nevertheless trained sales representatives to more broadly promote Juxtapid by intentionally failing to define HoFH, discouraging the use of genetic testing and established diagnostic criteria to identify HoFH patients, misleading prescribers regarding the clinical profiles of patients in the Juxtapid pivotal trial, and identifying patients whose clinical profiles did not meet established diagnostic criteria for HoFH;
  • trained sales representatives to tell prescribers and patients that using Juxtapid would prevent “impending” heart attacks or strokes, although Aegerion did not have data showing Juxtapid had a meaningful effect on cardiovascular mortality or morbidity;3 and
  • promoted Juxtapid for use as monotherapy, despite the drug’s indication as adjunctive therapy.

Noncompliance With Juxtapid REMS. The Information also alleges that Aegerion failed to comply with the Juxtapid REMS, which was designed to ensure that Juxtapid’s benefits outweighed the drug’s risk of liver toxicity by educating prescribers about that risk and restricting access to Juxtapid to patients with a diagnosis consistent with HoFH. The Information asserts that Aegerion was responsible for implementing, maintaining, monitoring and evaluating the REMS but violated 21 U.S.C. § 352(f) when:

  • sales representatives advised prescribers that they could sign required REMS attestations for patients whose clinical profiles did not meet established diagnostic criteria for HoFH, completed attestations without prescribers’ knowledge, and included false and misleading information in statements of medical necessity to make patients appear to be HoFH patients on forms submitted to FDA about the REMS program;
  • Aegerion failed to conduct REMS training for physicians who supervised nurse practitioners who were prescribing Juxtapid; and
  • Aegerion provided misleading information regarding who was being prescribed Juxtapid to FDA in a required REMS assessment report.

Plea Agreement. In addition to pleading guilty to the two-count Information, Aegerion agreed to pay a $6.2 million criminal fine and $1 million in restitution. The plea agreement also requires that for three years, Aegerion, its president and its parent company’s board of directors annually review and certify compliance with the plea agreement and consent decree.

Consent Decree. The consent decree requires Aegerion to comply with the Juxtapid REMS, retain an independent auditor to annually audit and monitor its REMS compliance for a period of five years and remediate any noncompliance within specified time frames. If FDA determines that Aegerion has failed to comply with the consent decree or FDCA, it may take various administrative actions (including ordering Aegerion to cease selling, detailing or distributing Juxtapid), pursue further civil or criminal penalties, or impose stipulated financial penalties.

Analysis of FDCA Resolutions. The theories of FDCA liability and the resulting resolutions in the Aegerion case are notable for a number of reasons. First, in recent years, many industry observers have noted a marked decline in criminal cases based on alleged off-label promotion.4 The resolution in Aegerion, however, shows that DOJ and FDA will still pursue criminal charges in off-label promotion cases, particularly where certain “aggravating factors” are present. In the case of Aegerion, those factors appear to have been (1) flouting FDA’s regulatory authority — the Information asserts that Aegerion repeatedly represented to FDA that it would not promote the drug beyond the narrow HoFH indication; and (2) identified patient harm — the Information specifically alleges that numerous patients, including elderly and pediatric patients, suffered significant adverse events due to unapproved use of Juxtapid. In short, while the government has primarily pursued off-label cases through civil resolutions in recent years, companies should not assume that criminal off-label liability is off the table in appropriate cases.

Second, Aegerion is the second settlement this month to involve allegations that a pharmaceutical company failed to comply with its obligations under an FDA-mandated REMS program. On September 5, 2017, DOJ announced a $58 million civil settlement with Novo Nordisk that, among other things, resolved allegations that Novo Nordisk provided sales representatives with tactics to counter and neutralize the risk message required by the REMS for its Type II diabetes drug, Victoza. Following on the heels of the Novo Nordisk settlement, the Aegerion plea agreement and consent decree make clear that failure to comply with obligations under a REMS program creates both criminal and civil liability for companies subject to such programs. It also represents a novel use of the consent decree to address REMS compliance requirements, as historically, consent decrees have more often been imposed to address chronic manufacturing process deficiencies.

HIPAA Violations by Sales Personnel Result in Deferred Prosecution Agreement

Aegerion entered into a three-year DPA to resolve a charge that it conspired to violate HIPAA’s patient privacy provisions. According to the DPA’s agreed statement of facts, from January 2013 through 2015, Aegerion sales personnel obtained access to patients’ protected health information without the requisite patient authorization in order to market Juxtapid to physicians and patients. Aegerion acknowledged that at the direction of and with the approval of senior management, Aegerion sales employees violated HIPAA by (1) gaining access to physicians’ electronic medical record systems to identify potential patients for Juxtapid; (2) completing or assisting with completion of statements of medical necessity or prior authorizations for insurance coverage; (3) contacting patients directly to convince them to use Juxtapid or to obtain authorization to allow Aegerion customer service personnel to access their protected health information; (4) forging signatures on patient authorization forms; (5) obtaining patient signatures on HIPAA authorizations in English from non-English speaking patients who did not understand the nature of the HIPAA release; and (6) providing gifts or benefits to medical staff in exchange for access to patient data. The DPA also states that Aegerion sales managers and executives instructed sales employees to wear surgical scrubs in order to blend in with the office staff to facilitate access to HIPAA-protected information and implemented incentive compensation programs that motivated sales personnel to improperly access protected health information.

Under the terms of the DPA, Aegerion agreed to institute and maintain a compliance and ethics program designed to prevent, detect and correct HIPAA violations. The DPA imposes several certification and reporting obligations for Aegerion and its parent company’s board of directors as part of that compliance program. For example, the DPA requires Aegerion to maintain a log of all reports of questionable HIPAA-related practices by Aegerion employees, and Aegerion’s compliance officer is required to annually certify that the company maintained that log and report the number of log entries that relate to HIPAA. Aegerion’s president is required to annually certify the effectiveness of the company’s compliance program in detecting and preventing HIPAA violations, and the board of directors for Aegerion’s parent company (or any future parent company) must conduct a review of the effectiveness of the HIPAA compliance program and submit a resolution to the government as to its findings of that review. Finally, Aegerion must provide the government with quarterly reports of any reportable events that a reasonable person would consider a probable violation of HIPAA.

The Aegerion settlement follows the 2015 Warner Chilcott settlement, which also included a manufacturer’s plea to violations of HIPAA. These resolutions suggest that the government will pursue HIPAA charges even in instances where the target is not a covered entity under HIPAA. Both settlements involved allegations that sales personnel accessed patient files containing HIPAA-protected information, without permission, for commercial purposes. These settlements highlight the risk posed by having sales personnel involved in activities that give them access to protected health information.

Civil False Claims Act Settlement Resolves Allegations Regarding Inducements to Patients Through Donations to Copay Charity, Promotional Practices

Aegerion entered into a civil False Claims Act settlement (and related state settlements) and agreed to pay $28.8 million to resolve four discrete categories of covered conduct: (1) unlawfully inducing patients to purchase Juxtapid by channeling donations to a charitable patient assistance organization where Aegerion participated in the creation of the fund and in establishing the criteria for coverage to facilitate copays for Juxtapid; (2) distributing Juxtapid for uses beyond “medically accepted indication[s]” that were thus not reimbursable by federal health care programs; (3) making false and misleading statements about the safe and effective use of Juxtapid, which circumvented the FDA-required REMS; and (4) providing (and instructing physicians to provide) false information in prior authorization forms and letters of medical necessity that were provided to health insurers.

Although much of this alleged conduct is addressed through other components of the resolution, only the civil settlement addresses Aegerion’s donations to third-party charitable organizations. This part of the settlement is notable because patient assistance programs are an area of intense government scrutiny. The Aegerion resolution represents the second time that DOJ has publicly articulated a theory that manufacturer donations to a patient assistance organization may violate the AKS when the charity does not operate with sufficient independence from the manufacturer and the manufacturer’s donations disproportionately benefit its patients.

CIA Establishes Rigorous Oversight Requirements and Includes New Controls for Relationships With Independent Copay Charities

Aegerion’s five-year CIA incorporates many of the most rigorous oversight provisions found in recent pharmaceutical company CIAs. Some noteworthy provisions of Aegerion’s CIA include:

  • The compliance obligations imposed on the board of directors apply to the board of Novelion Therapeutics, Aegerion’s foreign-based parent.
  • The chief compliance officer must report to the president of Aegerion and the global chief compliance officer at Novelion.
  • Management certifications are required by officers of both Novelion and Aegerion.
  • A financial recoupment program must be implemented that puts up to three years of annual performance pay at risk for specific covered executives if certain types of misconduct occur.
  • An annual risk assessment and mitigation process must be implemented.
  • Aegerion must conduct field force monitoring activities.

In addition, the Aegerion CIA is the first to include reasonably specific compliance controls focused on a drug manufacturer’s relationship with and donations to an independent patient assistance charity. These controls include strict separation of patient assistance program decision-making from commercial personnel, limits on interactions with copay charities and internal rules regarding the budgeting process for donations to copay charities.

Implications for Drug and Device Manufacturers

The Aegerion global settlement is sweeping in its scope and detail. The settlement addresses alleged misconduct in several emerging risk areas, including compliance with FDA-mandated REMS requirements, access to protected health information under HIPAA, the accuracy and completeness of prior authorization and letters of medical necessity provided by companies to insurers, and relationships with and donations to charitable copay foundations.

The collection of documents generated by the settlement provides companies with an opportunity to assess their existing compliance programs and controls against those found in the Aegerion settlement materials, particularly in areas where government guidance has not been forthcoming. In addition, the Aegerion case reinforces the importance of assessing the drivers of behaviors (including but not limited to incentive compensation) and the role such drivers might play in encouraging or incentivizing improper conduct.

______________________

1 The company also resolved allegations by the Securities and Exchange Commission (SEC) relating to the company’s disclosure practices. The SEC settlement is outside the scope of this client alert.

2 United States ex rel. Clarke, et al. v. Aegerion Pharmaceuticals, Inc., et al., No. 13-CV-11785 (D. Mass.).

3 Notably, in November 2013, FDA issued a warning letter to Aegerion regarding public statements the company’s CEO had made that FDA determined misleadingly suggested Juxtapid was safe and effective in decreasing the occurrence of cardiovascular events including heart attacks and strokes. The letter noted the limitation of use in Juxtapid’s prescribing information stating that the effect of the drug on cardiovascular morbidity and mortality had not been determined.

4 DOJ has pursued few criminal off-label promotion cases since the U.S. Court of Appeals for the Second Circuit’s 2012 ruling in United States v. Caronia that the FDCA neither prohibits nor criminalizes truthful, nonmisleading speech that may constitute off-label promotion of an approved prescription drug. 703 F.3d 149 (2d Cir. 2012). At the same time, however, DOJ and state attorneys general have continued to pursue off-label promotion through civil settlements and, in the past 19 months, have recovered more than $716.5 million in four settlements based, at least in part, on improper promotional claims. SeeRecent Settlements Suggest Off-Label Cases Aren’t Extinct,” John Bentivoglio, Jennifer Bragg, Avia Dunn and Elizabeth Berry, Law360 (August 30, 2017).

Download pdf

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Skadden, Arps, Slate, Meagher & Flom LLP | Attorney Advertising

Written by:

Skadden, Arps, Slate, Meagher & Flom LLP
Contact
more
less

Skadden, Arps, Slate, Meagher & Flom LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.